When we examined the drug response data from the Genomics of Drug Sensitivity in Cancer (GDSC, https://www.cancerrxgene.org) along with gene expression data from the Cancer Cell Line Encyclopedia (CCLE) [48], it also showed that breast cancer cell lines with higher UBE2S expression exhibited enhanced sensitivity to olaparib with lower IC50 (Fig 6C). This evidence concerns the gene UBE2S and breast carcinoma.